Canavan Disease

Canavan Disease

Introduction

Canavan Disease is a progressive neurodegenerative disorder characterized by the gradual loss of neuronal function. This page provides comprehensive information about the disease, including its pathophysiology, clinical presentation, diagnosis, and current therapeutic approaches.

Overview

Canavan disease (CD) is a rare, autosomal recessive [leukodystrophy caused by deficiency of the enzyme aspartoacylase (ASPA), which hydrolyzes N-acetylaspartic acid (NAA) into aspartate and acetate. The resulting accumulation of NAA in the brain leads to progressive spongy degeneration of cerebral white matter, severe dysmyelination, and devastating neurological decline. Canavan disease was first described by Myrtelle Canavan in 1931 and the enzymatic defect was identified by Reuben Matalon in 1988 ([Matalon et al., 1988](https://doi.org/10.1002/ajmg.1320290408)). [@measurement]

Canavan disease is classified among the lysosomal and metabolic storage disorders that cause neurodegeneration. At the molecular level, most disease-linked ASPA variants lead to structural destabilization and proteasomal degradation of the protein, making CD fundamentally a protein misfolding disorder — connecting it to the proteostasis failure mechanisms seen in other neurodegenerative diseases ([Bitto et al., 2007](https://doi.org/10.1093/hmg/ddm137)). [@human]

Epidemiology

Canavan disease occurs in all ethnic groups but is most prevalent among individuals of Ashkenazi Jewish descent: [@discovery]

Canavan Disease

Introduction

Canavan Disease is a progressive neurodegenerative disorder characterized by the gradual loss of neuronal function. This page provides comprehensive information about the disease, including its pathophysiology, clinical presentation, diagnosis, and current therapeutic approaches.

Overview

Canavan disease (CD) is a rare, autosomal recessive [leukodystrophy caused by deficiency of the enzyme aspartoacylase (ASPA), which hydrolyzes N-acetylaspartic acid (NAA) into aspartate and acetate. The resulting accumulation of NAA in the brain leads to progressive spongy degeneration of cerebral white matter, severe dysmyelination, and devastating neurological decline. Canavan disease was first described by Myrtelle Canavan in 1931 and the enzymatic defect was identified by Reuben Matalon in 1988 ([Matalon et al., 1988](https://doi.org/10.1002/ajmg.1320290408)). [@measurement]

Canavan disease is classified among the lysosomal and metabolic storage disorders that cause neurodegeneration. At the molecular level, most disease-linked ASPA variants lead to structural destabilization and proteasomal degradation of the protein, making CD fundamentally a protein misfolding disorder — connecting it to the proteostasis failure mechanisms seen in other neurodegenerative diseases ([Bitto et al., 2007](https://doi.org/10.1093/hmg/ddm137)). [@human]

Epidemiology

Canavan disease occurs in all ethnic groups but is most prevalent among individuals of Ashkenazi Jewish descent: [@discovery]

• Ashkenazi Jewish population: Carrier frequency of approximately 1 in 37–40; disease incidence estimated at 1 in 6,400–13,500 births ([Feigenbaum et al., 2004](https://doi.org/10.1002/ajmg.c.30015))
• General population: Carrier frequency approximately 1 in 200; exact incidence unknown but significantly lower
• Other populations: Cases reported in diverse ethnic backgrounds including Saudi Arabian, Turkish, European, and Indian populations
• Inheritance: Autosomal recessive; both parents must carry a pathogenic ASPA variant

Genetics and Molecular Biology

The ASPA Gene

The ASPA gene is located on chromosome 17p13.2, spans approximately 29 kilobases, and contains 6 exons. It encodes aspartoacylase, a 35.7 kDa enzyme of 313 amino acid residues that catalyzes the hydrolysis of N-acetyl-L-aspartic acid (NAA) into L-aspartate and acetate ([Kaul et al., 1993](https://doi.org/10.1016/S0888-7543(05)80064-3)). [@aspa]

More than 80 pathogenic ASPA variants have been identified, including: [@nacetylaspartate]

• p.Glu285Ala (E285A): Most common in Ashkenazi Jewish patients (~83% of alleles)
• p.Tyr231Ter (Y231X): Second most common (~13% of Ashkenazi alleles)
• p.Ala305Glu (A305E): Common in non-Jewish European patients

N-Acetylaspartic Acid (NAA)

NAA is the second most abundant amino acid derivative in the brain (after [glutamate), with concentrations of 8–10 mM in normal brain tissue. It is synthesized primarily in [neurons](/entities/neurons) by aspartate N-acetyltransferase (NAT8L) from acetyl-CoA and aspartate ([Moffett et al., 2007](https://doi.org/10.1016/j.pneurobio.2007.02.006)). [@naa]

Key functions of NAA and its metabolites: [@loss]

Pathogenic Mechanisms

Loss of ASPA activity causes NAA accumulation to levels 5–10 times normal, leading to multiple pathological consequences: [@white]

Clinical Presentation

Neonatal/Infantile Form (Most Common)

The neonatal/infantile form accounts for >90% of Canavan disease cases and presents in the first months of life ([Matalon et al., 1995](https://pubmed.ncbi.nlm.nih.gov/8528214/)): [^11]

• Early signs (1-3 months): Hypotonia, poor head control, feeding difficulties, macrocephaly
• Motor regression (3-6 months): Loss of acquired motor milestones, progressive spasticity replacing hypotonia
• Characteristic features: Severe macrocephaly (head circumference >98th percentile), optic atrophy, seizures
• MRI findings: Diffuse symmetric white matter involvement with elevated NAA on MR spectroscopy — pathognomonic for Canavan disease ([Barkovich & Patay, 2019](https://pubmed.ncbi.nlm.nih.gov/30820731/))
• Progression: Decerebrate posturing, inability to sit independently, dysphagia requiring gastrostomy
• Prognosis: Most patients survive into childhood; death typically occurs in the first decade from respiratory complications or status epilepticus

Juvenile Form (Rare)

The juvenile form of Canavan disease is rare and presents with a milder, later-onset phenotype ([Traeger & Bhatt, 2015](https://pubmed.ncbi.nlm.nih.gov/26026073/)): [^12]

• Age of onset: Typically 4-5 years, though cases presenting in adolescence have been described
• Clinical features: Speech delay, mild motor difficulties, and learning disabilities; macrocephaly may be absent or mild
• Cognitive trajectory: Slow cognitive decline rather than the rapid regression seen in the infantile form; some patients maintain ambulation and limited verbal communication into adulthood
• Imaging: Milder white matter changes on MRI; NAA elevation on MR spectroscopy is present but less pronounced
• Genotype: Often associated with compound heterozygous or hypomorphic ASPA mutations that retain partial enzyme activity
• Prognosis: Significantly better than infantile form; survival into adulthood is common

Neuropathology

The hallmark neuropathological finding in Canavan disease is spongy degeneration of the cerebral white matter: [^13]

• Macroscopic: Megalencephaly (brain weight up to 2x normal), gelatinous white matter
• Microscopic: Widespread vacuolation within myelin sheaths and between cortical layers, predominantly affecting subcortical white matter, [cerebral [cortex](/brain-regions/cortex), and [cerebellum](/brain-regions/cerebellum) ([Adachi et al., 1973](https://doi.org/10.1007/BF00685083))
• Cellular changes: [astrocytes](/cell-types/astrocytes) swelling with [Alzheimer](/diseases/alzheimers-disease) type II changes, [oligodendrocytes](/entities/oligodendrocytes) loss, relative preservation of [neurons](/entities/neurons) until late stages
• Regional vulnerability: Subcortical U-fibers and deep white matter most severely affected; [basal-ganglia](/brain-regions/basal-ganglia) and [thalamus](/brain-regions/thalamus) variably involved

Diagnosis

Clinical and Neuroimaging

• MRI: Diffuse, bilateral, symmetric T2/FLAIR hyperintensity involving subcortical white matter, beginning in the occipital regions. The [thalamus](/brain-regions/thalamus) and globus pallidus may also be affected ([Brismar et al., 1990](https://doi.org/10.3174/ajnr.A1176))
• MR Spectroscopy: Elevated NAA peak is virtually pathognomonic — distinguishes Canavan disease from other leukodystrophies
• CT: Diffuse white matter hypodensity

Biochemical Testing

• Urine NAA: Markedly elevated (5–20 times normal) — the primary screening test
• Blood NAA: Elevated but less specific
• ASPA enzyme activity: Reduced in cultured fibroblasts (confirmatory but rarely needed)

Genetic Testing

• ASPA gene sequencing: Identifies pathogenic variants; standard confirmatory test
• Carrier screening: Recommended for Ashkenazi Jewish individuals and partners of known carriers
• Prenatal diagnosis: Available via chorionic villus sampling or amniocentesis

Treatment and Management

Current Standard of Care

There is currently no approved cure for Canavan disease. Management is supportive: [^14]

• Physical and occupational therapy: To maintain function and manage spasticity
• Nutritional support: Gastrostomy tube feeding for swallowing difficulties
• Seizure management: Antiepileptic medications as needed
• Respiratory care: Management of aspiration risk and respiratory complications

Gene Therapy (Investigational)

Gene therapy represents the most promising therapeutic approach for Canavan disease:

Myrtelle rAAV-Olig001-ASPA (MYR-101)
The first gene therapy specifically targeting [oligodendrocytes](/entities/oligodendrocytes) using the novel Olig001 AAV capsid. Phase 1/2 clinical trial results published in Nature Medicine (2025) demonstrate:

• >80% reduction in CSF NAA levels in all seven treated patients at 24 months
• Increases in brain white matter and myelin volume on MRI
• FDA Rare Pediatric Disease, Orphan Drug, and Fast Track designations

BridgeBio BBP-812
An AAV9-based gene therapy being evaluated in the Phase 1/2 CANaspire trial:

• Six children treated with dramatic NAA reductions in urine
• One patient reportedly achieved independent sitting and first steps
• Further data expected in 2026

Experimental Approaches

• Lithium citrate: Showed some benefit in preclinical models by reducing NAA through decreased NAT8L activity ([Assadi et al., 2010](https://doi.org/10.1212/WNL.0b013e3181f609e4))
• Triheptanoin: Anaplerotic therapy to provide alternative carbon sources for myelin synthesis
• Stem cell transplantation: Under investigation; human neural stem cells have shown some preclinical benefit
• Enzyme replacement therapy: Challenging due to [blood-brain-barrier](/entities/blood-brain-barrier) penetration requirements

Animal Models

Several animal models have been instrumental in understanding CD pathogenesis and developing therapies:

• ASPA knockout mouse (Aspanur7): Naturally occurring tremor rat model; recapitulates spongy degeneration and elevated NAA
• CD transgenic mouse: Created by targeted disruption of ASPA gene; used extensively for gene therapy studies
• AAV-treated mouse models: Have demonstrated proof of concept for gene therapy, with near-complete correction of NAA levels and pathology when treated early ([Ahmed et al., 2013](https://doi.org/10.1038/mt.2012.198))

See Also

• [All Diseases

Background

The study of Canavan Disease has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/) - Biomedical literature
• [Alzheimer's Disease Neuroimaging Initiative](https://adni.loni.usc.edu/) - Research data
• [Allen Brain Atlas](https://brain-map.org/) - Brain gene expression data

Recent Research (2024-2026)

This section highlights recent publications relevant to this disease.

• [Prolonged Survival in Mesothelioma Patients Without Surgical Resection: A National Cancer Database Analysis.](https://pubmed.ncbi.nlm.nih.gov/40588180/) (2026 Mar) - The Annals of thoracic surgery
• [Measurement of Motor Function in Children With Canavan Disease: Concordance Between Remote and In-Person Assessments.](https://pubmed.ncbi.nlm.nih.gov/41806495/) (2026 Feb 18) - Pediatric neurology
• [Human iPSC-derived neural progenitor cells rescue motor function and brain pathology in symptomatic Canavan disease mice.](https://pubmed.ncbi.nlm.nih.gov/41576940/) (2026 Feb 10) - Stem cell reports
• [Discovery of N-Acetyltransferase 8-Like (NAT8L) inhibitors based on a N-Acylated (Piperidin-3-ylmethyl)-1,2,4-Oxadiazole Scaffold.](https://pubmed.ncbi.nlm.nih.gov/41675922/) (2026 Feb 3) - ACS medicinal chemistry letters
• [Minimal important difference of quadriceps maximal voluntary contraction (QMVC) in COPD: a prospective cohort study.](https://pubmed.ncbi.nlm.nih.gov/41593004/) (2026 Jan 27) - Thorax

Visual Summary

Key Pathway Steps:

References